Engineering resting B cells for the suppression of unwanted immunity

Project 2

Project leader:

Dr. rer. nat. Simon Fillatreau

Deutsches Rheuma-Forschungszentrum

Postal address:

Charitéplatz 1

10117 Berlin

t: +49 30 28460 761

f: +49 30 28460 604



Resting B cells are known as tolerogenic antigen-presenting cells for more than 20 years. We have developed a novel protocol to introduce selected genes in resting B cells in absence of any activation. Such resting modified B cells protected recipient mice from experimental autoimmune encephalomyelitis (EAE) upon adoptive transfer. Our project aims at understanding and improving the efficacy of this cellular therapy using autoimmune diseases of the central nervous system and type 1 diabetes as models.



Research Database

For more details please use the Charité undefinedresearch database.